Kaatz G W, Seo S M
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Antimicrob Agents Chemother. 1997 Dec;41(12):2733-7. doi: 10.1128/AAC.41.12.2733.
Fluoroquinolone resistance in Staphylococcus aureus results from amino acid substitutions at particular locations in the DNA gyrase A and B subunits as well as in the topoisomerase IV A subunit and from NorA-mediated efflux. More than one resistance mechanism may be present in a single strain. Fluoroquinolone-resistant derivatives of SA-1199, a methicillin-susceptible S. aureus strain, were selected in vivo or in vitro, and their mechanisms of fluoroquinolone resistance were identified. We found that many of the resistance mechanisms described above can develop in derivatives of a single parent strain, either singly or in combination, and can arise in a single step. Variances in MICs for strains with the same apparent resistance mechanisms likely are due to the presence of new or undetected but established means of fluoroquinolone resistance. NorA-mediated resistance can occur in the apparent absence of topoisomerase mutations and in some strains may be the result of a promoter region mutation causing increased expression of norA. However, increased expression of norA can occur independently of this mutation, suggesting that a regulatory locus for this gene exists elsewhere on the chromosome.
金黄色葡萄球菌对氟喹诺酮类药物的耐药性源于DNA旋转酶A和B亚基以及拓扑异构酶IV A亚基特定位置的氨基酸取代,以及NorA介导的外排作用。单个菌株中可能存在不止一种耐药机制。在体内或体外筛选出了对甲氧西林敏感的金黄色葡萄球菌菌株SA - 1199的氟喹诺酮耐药衍生物,并确定了它们对氟喹诺酮的耐药机制。我们发现,上述许多耐药机制可以在单个亲本菌株的衍生物中单独或联合出现,并且可以在一步中产生。具有相同明显耐药机制的菌株在最低抑菌浓度(MIC)上的差异可能是由于存在新的或未检测到但已确定的氟喹诺酮耐药方式。NorA介导的耐药性可能在明显不存在拓扑异构酶突变的情况下发生,并且在某些菌株中可能是启动子区域突变导致norA表达增加的结果。然而,norA的表达增加可以独立于这种突变发生,这表明该基因的调控位点存在于染色体的其他位置。